Car T-Cell Therapy
Early intrathecal therapy shows promise for managing neurotoxicity related to CAR-T
Early intrathecal therapy effectively resolved symptoms related to high-grade neurotoxicity among patients who received chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma, according to a research letter in JAMA Oncology.
Cleveland Clinic appoints cancer immunology expert as program director
J. Joseph Melenhorst, PhD, has been appointed director of Cleveland Clinic’s new cell therapy and immuno-engineering program.
FDA grants orphan drug status to CAR-T for T-cell acute lymphoblastic leukemia
The FDA granted orphan drug designation to WU-CART-007 for patients with relapsed or refractory T-cell acute lymphoblastic leukemia.
Spotlight on multiple myeloma: New drug approvals highlight treatment advances
Myeloma Awareness Month is observed in March.
FDA grants fast track designation to donor-derived CAR-T for advanced kidney cancer
The FDA granted fast track designation to ALLO-316, an investigational chimeric antigen receptor T-cell therapy, for the treatment of adults with advanced or metastatic clear cell renal cell carcinoma.
VIDEO: CAR T-cell therapy ‘showed efficacy’ in prostate cancer subgroup
Healio spoke with Tanya Dorff, MD, section chief of the genitourinary disease program at City of Hope, about a study evaluating the use of a chimeric antigen receptor T-cell therapy in a subgroup of patients with prostate cancer.
Top in hem/onc: Healio’s Wordle-like game, CAR T-cell therapy trial
Two years into the COVID-19 pandemic, some light-hearted fun is long overdue for health care providers. Therefore, Healio launched its own Wordle-like game for clinicians. The announcement was the top story in hematology/oncology last week.
VIDEO: PSCA-targeted CAR T-cell therapy shows promise in prostate cancer subgroup
In this video, Tanya Dorff, MD, discusses findings from a phase 1 study assessing prostate stem cell antigen-targeted CAR T-cell therapy in patients with castration-resistant prostate cancer.
Top in hem/onc: Researchers pause CAR-T trial, no link between meat and colon cancer
Memorial Sloan Kettering Cancer Center paused a phase 1 trial for a chimeric antigen receptor T-cell therapy to investigate the death of a patient who received the treatment. It was the top story in hematology/oncology last week.
CAR T-cell therapy trial paused after two patient deaths
Celyad Oncology placed a voluntary pause on a clinical trial of CYAD-101 after two patients treated with the investigational chimeric antigen receptor T-cell therapy died.